文献速递胃肠外科围术期管理与 ERAS

GERDx™全层内镜下折叠装置治疗GERD的前瞻性试验

Clinical feasibility of a new full-thickness endoscopic plication device (GERDx™) for patients with GERD: results of a prospective trial.
PubMed 文献 · Surg Endosc · 2018-03-30

结果显示无术中并发症,4例出现需干预的术后并发症,7例因症状持续改行腹腔镜胃底折叠术;30例完成3个月随访,GIQLI评分、反流症状评分及DeMeester评分均显著改善,食管测压数据无显著变化。

要点

  • GERDx™内镜下折叠可显著改善GERD患者生活质量与反流症状
  • 3个月随访时食管测压数据无显著变化,3/30例仍需每日抗反流药物

核心结论

  • 在选定GERD患者中,GERDx™内镜下折叠可减少食管远端酸暴露、改善反流相关症状和GIQLI评分,副作用轻微,可能是一种安全的替代治疗。

研究设计与样本

  • 纳入标准为至少一种典型反流症状且PPI治疗>6个月、存在病理性食管酸暴露、食管裂孔疝<2 cm、内镜Hill分级II-III。
  • 在基线和术后3个月评估GIQLI、症状评分、食管测压和阻抗-pH监测。

主要发现

  • GIQLI评分从均值92.45 ± 18.47改善至112.03 ± 13.11(p < 0.001)。
  • 反流特异性评分从均值49.84 ± 24.83降至23.93 ± 15.63(p < 0.001),DeMeester评分从均值46.48 ± 30.83降至20.03 ± 23.62(p < 0.001)。
  • 食管测压数据无显著变化;3/30例继续每日抗反流药物治疗。

临床怎么用

  • 对于符合入选标准(PPI治疗>6个月仍有症状、病理性酸暴露、食管裂孔疝<2 cm、Hill分级II-III)的GERD患者,可考虑GERDx™内镜下折叠作为治疗选择。
  • 术后需监测并发症,部分患者可能因症状持续需转为腹腔镜胃底折叠术。

局限性

  • 单臂设计,缺乏对照组。
  • 随访时间仅3个月,长期疗效未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous studies suggest clinical effectiveness of endoscopic full-thickness plication in selected patients with gastroesophageal reflux disease (GERD). The aim of this study was to assess the clinical safety and efficiency of the GERDx™ device by evaluating clinical parameters, reflux symptom scores, and quality of life (QoL). METHODS: Prospective one-arm trial evaluating the outcome of forty patients with GERD subjected to endoscopic plication with the GERDx™ device. We included patients with at least one typical reflux symptom despite treatment with a PPI for > 6 months, pathologic esophageal acid exposure, hiatal hernia of size < 2 cm, and endoscopic Hill grade II-III. Evaluation of Gastrointestinal Quality of Life Index (GIQLI), symptom scores, esophageal manometry, and impedance-pH-monitoring were performed at baseline and at 3 months after surgery. (Trial Registration: ClinicalTrials.gov NCT 01798212.) RESULTS: There were no intraoperative complications. Four out of forty patients experienced postoperative complications requiring intervention. Seven of forty patients were subjected to laparoscopic fundoplication 3 months after endoscopic plication due to persistent symptoms and were lost to further follow-up. Thirty out of forty patients were available at 3-month follow-up. There was an improvement of the GIQLI score, from a mean of 92.45 ± 18.47 to 112.03 ± 13.11 (p < 0.001). The general reflux-specific score increased from a mean of 49.84 ± 24.83 to 23.93 ± 15.63 (p < 0.001), and the DeMeester score from a mean of 46.48 ± 30.83 to 20.03 ± 23.62 (p < 0.001). There was no significant change in manometric data after intervention. Three of thirty patients continued daily antireflux medication. CONCLUSIONS: Endoscopic plication with the GERDx™ device reduced distal acid exposure of the esophagus, reflux-related symptoms, and improved GIQLI scores with minimal side effects in a selected cohort of patients and may be a safe alternative in the treatment of GERD.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Weitzendorfer M, Spaun GO, Antoniou SA, et al. Clinical feasibility of a new full-thickness endoscopic plication device (GERDx™) for patients with GERD: results of a prospective trial. Surg Endosc. 2018. PMID: 29602998. doi:10.1007/s00464-018-6153-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。